- Home
- AKA vs ZNTL Comparison
AKA vs ZNTL Comparison
Compare AKA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | ZNTL |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 118.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AKA | ZNTL |
|---|---|---|
| Price | $12.00 | $2.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $24.33 | $5.87 |
| AVG Volume (30 Days) | 4.3K | ★ 2.5M |
| Earning Date | 03-05-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,281,000.00 | $26,865,000.00 |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $7.00 | $1.01 |
| 52 Week High | $18.41 | $3.95 |
Technical Indicators
Market Signals| Indicator | AKA | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 61.23 |
| Support Level | $11.50 | $2.80 |
| Resistance Level | $12.29 | $3.95 |
| Average True Range (ATR) | 0.69 | 0.44 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 75.84 | 61.64 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.